Truist Securities Maintains Buy on Edwards Lifesciences, Raises Price Target to $110
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained its Buy rating on Edwards Lifesciences (NYSE:EW) and raised the price target from $105 to $110.
July 16, 2024 | 1:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has maintained its Buy rating on Edwards Lifesciences and raised the price target from $105 to $110.
The Buy rating and increased price target from a reputable analyst firm like Truist Securities is likely to positively impact investor sentiment and drive short-term price appreciation for Edwards Lifesciences.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100